C. Yong Kang
Professor
Postdoc: University of Wisconsin-Madison, USA
PhD: McMaster University, Canada
Office: Siebens-Drake Research Institute, Room 129
Phone: 519.661.3226
Email: cykang@uwo.ca
Lab Website: Kang Lab Website
Area of Study:
Development of vaccines against human viral diseases
Research Profile
The Kang Lab has developed HIV vaccine using a genetically modified and killed whole-HIV-1 (SAV001) and completed the Phase I human clinical trial successfully. His team is now preparing for the Phase II human clinical trial. He has also developed a dual-serotype VSV vector system for recombinant vaccine development using genetically modified avirulent M gene mutants of both Indiana serotype and New Jersey serotype of VSV. With this platform technology Kang Lab has developed vaccines against HIV, MERS-CoV, Ebolavirus, and Zikavirus. He has published 142 peer reviewed papers and 161 conference proceedings & abstracts. He has 14 international patents covering over 75 countries.
Publication Profile
Selected Publications:
DOI:10.15406/jhvrv.2016.04.00125, 2016
DOI:10.1186/s12977-016-0317-2, http://rdcu.be/m4U0, 2016
DOI:10.1186/s12981-017-0176-5, 2017
https://insight.jci.org/articles/view/126047 2019